Endothelial arginase II responds to pharmacological inhibition by elevation in protein level

Karina Krotova; Jawaharlal M. Patel; Edward R. Block; Sergey Zharikov

doi:10.1007/s11010-010-0515-5

Endothelial arginase II responds to pharmacological inhibition by elevation in protein level

Karina Krotova, Jawaharlal M. Patel, Edward R. Block, Sergey Zharikov

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Arginase is an enzyme which converts arginine to ornithine and urea. Recently, arginase has been implicated in many physiological and pathological processes including vascular diseases. Inhibition of arginase activity by pharmacological inhibitors is a useful tool to study the biology of arginases and their possible role in therapy. There are several arginase-specific inhibitors commercially available. Herein, we show that some of these inhibitors lead to an increase in arginase II protein level and activity. These effects should be anticipated when these inhibitors are in use or during the testing of new arginase inhibitors.

Original language	English (US)
Pages (from-to)	211-216
Number of pages	6
Journal	Molecular and cellular biochemistry
Volume	343
Issue number	1-2
DOIs	https://doi.org/10.1007/s11010-010-0515-5
State	Published - Oct 2010
Externally published	Yes

Bibliographical note

Funding Information:
Acknowledgments This study was supported in part by National Institutes of Health Grants HL-68607, HL-85133 and VA Merit Review (to J.M.P), as well as Florida DOH Grant 08KN-08-17234 (to K.K.).

Keywords

Arginase
Arginase inhibitors
Endothelium

Publisher link

10.1007/s11010-010-0515-5

Find It

Find It at U of M Libraries

Cite this

@article{b13b04ce83df4097a12db558dbce8a73,

title = "Endothelial arginase II responds to pharmacological inhibition by elevation in protein level",

abstract = "Arginase is an enzyme which converts arginine to ornithine and urea. Recently, arginase has been implicated in many physiological and pathological processes including vascular diseases. Inhibition of arginase activity by pharmacological inhibitors is a useful tool to study the biology of arginases and their possible role in therapy. There are several arginase-specific inhibitors commercially available. Herein, we show that some of these inhibitors lead to an increase in arginase II protein level and activity. These effects should be anticipated when these inhibitors are in use or during the testing of new arginase inhibitors.",

keywords = "Arginase, Arginase inhibitors, Endothelium",

author = "Karina Krotova and Patel, {Jawaharlal M.} and Block, {Edward R.} and Sergey Zharikov",

note = "Funding Information: Acknowledgments This study was supported in part by National Institutes of Health Grants HL-68607, HL-85133 and VA Merit Review (to J.M.P), as well as Florida DOH Grant 08KN-08-17234 (to K.K.).",

year = "2010",

month = oct,

doi = "10.1007/s11010-010-0515-5",

language = "English (US)",

volume = "343",

pages = "211--216",

journal = "Molecular and cellular biochemistry",

issn = "0300-8177",

publisher = "Springer",

number = "1-2",

}

TY - JOUR

T1 - Endothelial arginase II responds to pharmacological inhibition by elevation in protein level

AU - Krotova, Karina

AU - Patel, Jawaharlal M.

AU - Block, Edward R.

AU - Zharikov, Sergey

N1 - Funding Information: Acknowledgments This study was supported in part by National Institutes of Health Grants HL-68607, HL-85133 and VA Merit Review (to J.M.P), as well as Florida DOH Grant 08KN-08-17234 (to K.K.).

PY - 2010/10

Y1 - 2010/10

N2 - Arginase is an enzyme which converts arginine to ornithine and urea. Recently, arginase has been implicated in many physiological and pathological processes including vascular diseases. Inhibition of arginase activity by pharmacological inhibitors is a useful tool to study the biology of arginases and their possible role in therapy. There are several arginase-specific inhibitors commercially available. Herein, we show that some of these inhibitors lead to an increase in arginase II protein level and activity. These effects should be anticipated when these inhibitors are in use or during the testing of new arginase inhibitors.

AB - Arginase is an enzyme which converts arginine to ornithine and urea. Recently, arginase has been implicated in many physiological and pathological processes including vascular diseases. Inhibition of arginase activity by pharmacological inhibitors is a useful tool to study the biology of arginases and their possible role in therapy. There are several arginase-specific inhibitors commercially available. Herein, we show that some of these inhibitors lead to an increase in arginase II protein level and activity. These effects should be anticipated when these inhibitors are in use or during the testing of new arginase inhibitors.

KW - Arginase

KW - Arginase inhibitors

KW - Endothelium

UR - http://www.scopus.com/inward/record.url?scp=77957549495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957549495&partnerID=8YFLogxK

U2 - 10.1007/s11010-010-0515-5

DO - 10.1007/s11010-010-0515-5

M3 - Article

C2 - 20563744

AN - SCOPUS:77957549495

SN - 0300-8177

VL - 343

SP - 211

EP - 216

JO - Molecular and cellular biochemistry

JF - Molecular and cellular biochemistry

IS - 1-2

ER -

Endothelial arginase II responds to pharmacological inhibition by elevation in protein level

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this